Sixty Years since Vasopressin Synthetic Preparation Followed by a Nobel Prize. Is it Time to Augment its Use in Cardiac Surgery?
MOJ Surgery · 2014
DOI: 10.15406/mojs.2014.01.00001 ↗Kurz gefasst
Fachartikel in der Zeitschrift MOJ Surgery, 2014. Verfasst von Stavros Siminelakis. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
hormone”. This hormone has been shown to have effects within minutes when administrated intravenously. AVP rapidly distributes from plasma into the extracellular fluid volume. It is metabolized by the liver and the kidneys, and a small proportion is eliminated with the urine. The plasma half-life is very short (4-20 min), resulting in the necessity of continuous infusion in order to maintain its effects. Vasopressin causes vasoconstriction in skin, skeletal muscle, and mesenteric blood vessels mediated via V1 receptors. Nonetheless, some studies have also suggested additional vasodilatory effects at low concentrations in selected vascular beds, including coronary, pulmonary, and cerebral arteries. Circulating AVP, acting via specific V1 receptors in the area postrema, modulates central cardiovascular regulation by augmenting the baroreflex inhibition of efferent sympathetic nerve activity, and therefore counterbalances the caused increase in peripheral resistance. Moreover, there is growing evidence for the existence of AVP receptors located on the presynaptic terminals of central sympathetic efferent nerves in the spinal cord, the stimulation of which may decrease sympathetic excitability. For more than 25 years vasopressin indications were restricted to treating polyuria in patients with diabetes insipidus, reducing blood loss in patients with gastrointestinal bleeding and increasing the mobility of the gastrointestinal system. It was only in the 1990s that it was first used for its potent vasopressor effects in patients with cardiac arrest [2], septic shock [3], drug intoxication [4] and for surgery of carcinoid tumors [5]. Since then there are several studies that have demonstrated the augmented vasoconstrictor action of vasopressin, which can persist for up to 2 h, in patients with hypotension not responding to high-dose norepinephrine, dopamine and fluid resuscitation [5,6]. Another important advantage of vasopressin is the less prominent vasoconstriction in the coronary and cerebral circulation compared to the rest of the circulation. In addition to the double beneficial action of vasopressin in the myocardium and brain, there is a protective action to the kidneys as well. The increased urine output is a remarkable result of infused vasopressin that, according to several studies, is caused by the increased MAP which, consequently, improves the glomerular filtration rate [7].
Zitieren
APA
Siminelakis, S. (2014). Sixty Years since Vasopressin Synthetic Preparation Followed by a Nobel Prize. Is it Time to Augment its Use in Cardiac Surgery?. MOJ Surgery. https://doi.org/10.15406/mojs.2014.01.00001
Vancouver
Siminelakis S. Sixty Years since Vasopressin Synthetic Preparation Followed by a Nobel Prize. Is it Time to Augment its Use in Cardiac Surgery?. MOJ Surgery. 2014. doi:10.15406/mojs.2014.01.00001
BibTeX
@article{Siminelakis2014,
author = {Siminelakis, Stavros},
title = {Sixty Years since Vasopressin Synthetic Preparation Followed by a Nobel Prize. Is it Time to Augment its Use in Cardiac Surgery?},
journal = {MOJ Surgery},
year = {2014},
doi = {10.15406/mojs.2014.01.00001}
}
EUVIMED